Alebund Pharmaceuticals (Jiangsu) (HKG:9637) said the over-allotment option of its Hong Kong initial public offering was fully exercised on Friday, according to a same-day Hong Kong bourse filing.
The biopharmaceutical company expects to raise about HK$184.7 million in additional net proceeds.
The exercise involved the issue of 8.51 million additional H-shares at HK$22.60 each, representing about 15% of the total offer shares available under the global offering.
Dealings in the over-allotment shares are expected to begin on July 29, the filing said.